Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30814172 | 1.00 | NPC1 (0.50) | NPC1TDP1EPHX2RAB9AKMT2A | |
| SCHEMBL3098924 | 0.89 | RAB9A (0.47) | NPC1TDP1EPHX2RAB9AKMT2A | |
| SCHEMBL3100935 | 0.87 | RXFP1 (0.48) | NPC1TDP1EPHX2RAB9AKMT2A | |
| SCHEMBL30814171 | 0.87 | RXFP1 (0.48) | NPC1TDP1EPHX2RAB9AKMT2A | |
| SCHEMBL3098545 | 0.87 | EPHX2 (0.65) | NPC1TDP1EPHX2RAB9AKMT2A | |
| SCHEMBL30814206 | 0.86 | L3MBTL1 (0.52) | NPC1TDP1EPHX2RAB9AKMT2A | |
| SCHEMBL3101926 | 0.86 | L3MBTL1 (0.52) | NPC1TDP1EPHX2RAB9AKMT2A | |
| SCHEMBL30814186 | 0.85 | EPHX2 (0.52) | NPC1TDP1EPHX2RAB9AKMT2A | |
| SCHEMBL3095209 | 0.85 | EPHX2 (0.52) | NPC1TDP1EPHX2RAB9AKMT2A | |
| SCHEMBL3111375 | 0.83 | RAB9A (0.54) | NPC1TDP1EPHX2RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| US-7601870-B2 | Such as Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; potassium channel modulators; epilepsy | H. LUNDBECK A/S (DK) | 2009-10-13 | — | — | US | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| EP-1791809-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-06-06 | — | — | EP | claimed |
| US-20060155121-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | claimed |
| WO-2006029623-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-23 | — | — | WO | claimed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | disclosed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | disclosed |
| US-7601870-B2 | Such as Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; potassium channel modulators; epilepsy | H. LUNDBECK A/S (DK) | 2009-10-13 | — | — | US | disclosed |
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | disclosed |
| EP-1983974-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
| EP-1791809-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-06-06 | — | — | EP | disclosed |
| US-20060155121-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2006029623-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118285-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | KCNQ4, KCNQ5, KCNQ1 | NPC1 539/4885TDP1 4703/4885EPHX2 2349/4885 |
| US-20060155121-A1 | Substituted aniline derivatives | UGT2B7, NAT1, CYP1A2 | NPC1 531/4885TDP1 2030/4885EPHX2 3893/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | NPC1 402/4885TDP1 2351/4885EPHX2 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.